Safety of efalizumab therapy in patients with moderate to severe psoriasis: An open-label extension of a phase IIIb trial

Drug Safety

Volumn 31, Issue 8, 2008, Pages 715-726

  Hamilton, Tiffani ^a,f   Menter, Alan ^b   Caro, Ivor ^c   Compton, Peter ^c   Sobell, Jeffrey ^d   Papp, Kim A ^e  

^a Atlanta Dermatology   (United States)

^b BAYLOR RESEARCH INSTITUTE   (United States)

^c GENENTECH INC   (United States)

^d SkinCare Physicians of Chestnut Hill   (United States)

^e PROBITY MEDICAL RESEARCH   (Canada)

^f Vein and Research Center LLC   (United States)

Author keywords

Efalizumab, adverse reactions; Psoriasis, treatment

Indexed keywords

EFALIZUMAB; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BASAL CELL CARCINOMA; BREAST CANCER; CANADA; CARCINOID; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL CARCINOMA; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; OPEN STUDY; OUTPATIENT CARE; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFECTION; MALE; MIDDLE AGED; NEOPLASMS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 47649109793     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831080-00008     Document Type: Article

References (27)

1. Mendonca CO, Burden AD. Current concepts in psoriasis and its treatment. Pharmacol Ther 2003 Aug; 99 (2): 133-47
2. Fisher VS. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis. J Manag Care Pharm 2005 Jan; 11 (1): 33-55
3. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996 Jun; 132 (6): 623-9
4. Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996 Nov; 35 Pt 1): 710-9
5. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2002; 25 (13): 913-27
6. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005 Apr; 152 (4): 597-615
7. van de Kerkhof PC, Vissers WH. Established treatments psoriasis. Curr Drug Targets Inflamm Allergy 2004 Jun; 3 (2): 145-56
8. van de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001 Jun; 26 (4): 356-61
9. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993 Mar; 28 (3): 454-9
10. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004 Mar; 50 (3): 416-30
11. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999 Sep; 41 (3 Pt 2): S25-8
12. Short MW, Vaughan TK. Sequential therapy using cyclosporine and acitretin for treatment of total body psoriasis. Cutis 2004 Sep; 74 (3): 185-8
13. Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin 2004 Oct; 22 (4): 467-76
14. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005 Dec 27; 102 (52): 19057-62
15. Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006 May; 45 (5): 605-14
16. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290 (23): 3073-80
17. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13
18. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005 Mar; 52 (3 Pt 1): 425-33
19. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-8
20. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004 Nov; 3 (6): 614-24
21. Gottlieb AB, Hamilton T, Caro I, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006; 54 (4 Suppl. 1): S154-63
22. Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf 2004 May; 13 (5): 295-8
23. Leonardi C, Toth D, Cather J, et al. A review of malignancies observed during efalizumab (Raptiva®) clinical trials for plaque psoriasis. Dermatology 2006; 213: 204-14
24. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003 Feb; 120 (2): 211-6
25. Leonardi C, Menter A, Hamilton T, et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2007; 158 (5): 1107-16
26. ClinicalTrials.gov. RESTORE: Raptiva® (efalizumab) evaluation of safety and treatment optimization. NCT00402818 [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00402818?term=Raptiva&rank= 4-RESTORE [Accessed 2008 Jun 15]
27. ClinicalTrials.gov. A study to evaluate psoriasis outcomes and safety events in patints with chronic moderate to severe plaque psoriasis (RESPONSE). NCT00096928 [online]. Available from URL: http://www.clinicaltrials.gov/ct2/ show/NCT00096928?term=NCT00096928&rank=1=RESPONSE [Accessed 2008 Jun 15]